Opus Genetics
IRD
37 hedge funds and large institutions have $4.13M invested in Opus Genetics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 14 closing their positions.
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
3.2% less ownership
Funds ownership: 13.6% → 10.4% (-3.2%)
24% less funds holding
Funds holding: 49 → 37 (-12)
39% less capital invested
Capital invested by funds: $6.78M → $4.13M (-$2.65M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$73.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.4K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$37.9K |
| 4 |
BlackRock
New York
|
+$17.7K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$17.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$450K |
| 2 |
Renaissance Technologies
New York
|
-$162K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$132K |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$118K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$113K |
IRD Hedge Fund Activity: Q2 2024 in Review
37 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2024, worth a combined $4.13M — down 39% from $6.78M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IRD and 3 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Jane Street, opening a new position worth an estimated $73.2K. The largest seller was MAI Capital Management, exiting entirely with an estimated $450K sold.
- 37 institutional investors held Opus Genetics (IRD) as of Q2 2024, down from 49 in Q1 2024.
- Funds reported $4.13M of Opus Genetics stock for Q2 2024, down 39% quarter-over-quarter.
- 3 funds opened new Opus Genetics positions in Q2 2024 and 14 closed out, a net change of -11 holders.
- The largest Opus Genetics buyer in Q2 2024 was Jane Street, an estimated $73.2K added.
- The largest Opus Genetics seller in Q2 2024 was MAI Capital Management, an estimated $450K sold.
Based on aggregated 13F filings for Q2 2024.